[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344009-105":59,"doc-detail-344009-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","thor-a-tmb-heterogeneity-adaptive-optimization-model-predicts-immunotherapy-response-using-clonal-genomic-features-in-group-structured-data","THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data","","With immune checkpoint inhibitors expanding across early and advanced cancers, a tumor-agnostic biomarker to prioritize patients is highly valued. Tumor mutation burden (TMB) measures nonsynonymous mutations in tumor DNA and links to neoantigen production, immune response, and clinical decisions. Yet conventional TMB use based on simple mutational counts misses clonal tumor structure and the multidimensional nature of prognostic signals. THOR treats patient subgroups as related entities and introduces a TMB heterogeneity-optimized regression that fuses information across subgroups. Simulations confirm improved parameter estimation, and clinical evaluation in 238 immunotherapy patients plus 2212 patients across 19 subgroups shows better response prediction and survival hazard stratification.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/thor-a-tmb-heterogeneity-adaptive-optimization-model-predicts-immunotherapy-response-using-clonal-genomic-features-in-group-structured-data/344009/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/thor-a-tmb-heterogeneity-adaptive-optimization-model-predicts-immunotherapy-response-using-clonal-genomic-features-in-group-structured-data/344009.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does THOR improve compared with conventional TMB approaches?","Question",{"text":112,"@type":113},"THOR enhances predictive performance by modeling TMB heterogeneity and incorporating tumor clonality and multiple clinical endpoints, rather than relying only on simple mutational counts.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does THOR handle patient subgroup information?",{"text":117,"@type":113},"THOR treats subgroups as related yet distinct entities and uses fusion techniques across subgroups to improve data sharing and interpretation.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports THOR’s effectiveness?",{"text":121,"@type":113},"Simulations validate THOR’s superiority in parameter estimation, and a structured clinical evaluation shows improved patient stratification and prognostic predictions in both a primary cohort and public datasets.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344009,1790865455,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Briefings in Bioinformatics, 2025, 26(1), bbae648  \n[https://doi.org/10.1093/bib/bbae648](https://doi.org/10.1093/bib/bbae648)  \nProblem Solving Protocol  \nTHOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data  \nYixuan Wang 1 ,‡, Yanfang Guan2 , 3 ,‡, Xin Lai2 , Yuqian Liu2 , Zhili Chang2 ,4 , Xiaonan Wang2 ,4 , Quan Wang1 , Jingjing Liu1 , Jian Zhao1 , Shuanying Yang5 , *, Jiayin Wang2 , *, Xiaofeng Song1 , *  \n1 Department of Biomedical Engineering, College of Automation Engineering, Nanjing University of Aeronautics and Astronautics, 29 Jiangjun Avenue, Jiangning, Nanjing 211106, China  \n2 School of Computer Science and Technology, Faculty of Electronics and Information Engineering, Xi’an Jiaotong University, 28 Xianning West Road, Beilin, Xi’an 710049, China  \n3 Geneplus-Beijing Institute, 8 Life Park Road, Changping, Beijing 102206, China  \n4 Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., 128 Huakang Road, Pukou, Nanjing 210032, China  \n5 Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Xi’an Jiaotong University, 3 Shangqin Road, Xincheng, Xi’an 710004, China  \n*[Corresponding authors. Shuanying Yang. E-mail:](Corresponding authors. Shuanying Yang. E-mail: yangshuanying@xjtu.edu.cn)[ yangshuanying@xjtu.edu.cn](Corresponding authors. Shuanying Yang. E-mail: yangshuanying@xjtu.edu.cn); [Jiayin Wang. E-mail:](Jiayin Wang. E-mail: wangjiayin@mail.xjtu.edu.cn)[ wangjiayin@mail.xjtu.edu.cn](Jiayin Wang. E-mail: wangjiayin@mail.xjtu.edu.cn); Xiaofeng Song.  \nE-mail: [xfsong@nuaa.edu.cn](xfsong@nuaa.edu.cn)  \n‡Yixuan Wang and Yanfang Guan contributed equally to this work.  \nAbstract  \nWith the increasing number of indications for immune checkpoint inhibitors in early and advanced cancers, the prospect of a tumoragnostic biomarker to prioritize patients is compelling. Tumor mutation burden (TMB) is a widely endorsed biomarker that quantifies nonsynonymous mutations within tumor DNA, essential for neoantigen production, which, in turn, correlates with the immune response and guides decision-making. However, the general clinical application of TMB—relying on simple mutational counts targeted at a single endpoint—does not adequately capture the complex clonal structure of tumors nor the multifaceted nature of prognostic indicators. This recognition has spurred the exploration of sophisticated high-dimensional regression techniques. Unfortunately, the limited cohort sizes in immunotherapy trials have hindered the full potential of these advanced methods. Our approach considers patient subgroups as related yet distinct entities, enabling precise tailoring and refinement to address subgroup-specific dynamics. Given the deficiencies and the constraints, we introduce a TMB heterogeneity-optimized regression (THOR) . This innovative model enhances the predictive capabilities of TMB by integrating tumor clonality and a diverse spectrum of clinical endpoints, further augmented by fusion techniques across subgroups to facilitate robust data sharing and interpretation. Our simulations validate THOR’s superiority in parameter estimation for statistical inference. Clinically, we assess the utility of THOR in a structured cohort of 238 cancer patients undergoing immunotherapy, supplemented by 2212 patients across 19 subgroups from public datasets. The forecast of the responses and comparison of survival hazards demonstrate that THOR significantly enhances patient stratification and prognostic predictions by incorporating complex immunogenetic biology and subgroup-specific dynamics.  \nKeywords: tumor clonal heterogeneity; endpoint integration; group-structured data; cancer immunotherapy; prognostic biomarker; penalized fusion strategy  \nIntroduction  \nThe expanding application of immune checkpoint inhibitors (ICIs) in cancer treatments illustrates the urgent requirement for robust, tumor-agnostic biomarkers ","cbCaicCJrzCfcE4C","https://ap.wps.com/l/cbCaicCJrzCfcE4C","pdf",1969916,15,"English","# Abstract\n# Introduction","[{\"question\":\"What does THOR improve compared with conventional TMB approaches?\",\"answer\":\"THOR enhances predictive performance by modeling TMB heterogeneity and incorporating tumor clonality and multiple clinical endpoints, rather than relying only on simple mutational counts.\"},{\"question\":\"How does THOR handle patient subgroup information?\",\"answer\":\"THOR treats subgroups as related yet distinct entities and uses fusion techniques across subgroups to improve data sharing and interpretation.\"},{\"question\":\"What evidence supports THOR’s effectiveness?\",\"answer\":\"Simulations validate THOR’s superiority in parameter estimation, and a structured clinical evaluation shows improved patient stratification and prognostic predictions in both a primary cohort and public datasets.\"}]","THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data | PDF",1790052757,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5729eb7469839062a73e38df65697f28.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11d1286875de631e9dc6358eee865f14.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11e18d410be06fad6e827eba0e6bb28a.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a3fd5ba7fc785e047af748985485e30.webp",980,1287]